ZYBT
Zhengye Biotechnology Holding Limited Ordinary Shares
NASDAQ: ZYBT · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$0.92
+4.70% today
Updated 2026-04-28
Market cap
$43.72M
P/E ratio
—
P/S ratio
0.28x
EPS (TTM)
$-0.06
Dividend yield
—
52W range
$1 – $14
Volume
0.3M
Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $214.07M | $260.27M | $211.65M | $186.36M | $186.36M |
| Revenue growth (YoY) | — | +21.6% | -18.7% | -12.0% | +0.0% |
| Cost of revenue | $88.67M | $106.75M | $81.80M | $95.06M | $95.06M |
| Gross profit | $125.39M | $153.52M | $129.85M | $91.30M | $91.30M |
| Gross margin | 58.6% | 59.0% | 61.4% | 49.0% | 49.0% |
| R&D | $11.37M | $13.42M | $11.90M | $12.79M | $12.79M |
| SG&A | $22.29M | $28.99M | $25.89M | $63.84M | $22.57M |
| Operating income | $52.38M | $65.83M | $44.99M | $17.17M | $16.44M |
| Operating margin | 24.5% | 25.3% | 21.3% | 9.2% | 8.8% |
| EBITDA | $70.12M | $85.55M | $72.10M | — | $42.60M |
| EBITDA margin | 32.8% | 32.9% | 34.1% | 0.0% | 22.9% |
| EBIT | $54.11M | $66.75M | $48.19M | $17.17M | $18.44M |
| Interest expense | $1.05M | $2.84M | $4.42M | $4.04M | $4.04M |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $38.96M | $46.73M | $31.46M | $11.31M | $11.31M |
| Net income growth (YoY) | — | +20.0% | -32.7% | -64.0% | +0.0% |
| Profit margin | 18.2% | 18.0% | 14.9% | 6.1% | 6.1% |